ArticleCureus2026
Left Ventricular Thrombus Despite Prescribed Direct Oral Anticoagulant Therapy in Chronic Heart Failure With Reduced Ejection Fraction: A Case Report and Review of Risk Stratification.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular thrombus (LVT) remains a clinically important complication associated with increased risks of systemic thromboembolism, ischemic stroke, and adverse cardiovascular outcomes. The optimal duration of anticoagulation treatment remains difficult to establish, and it should be individualized depending on patient characteristics. We present the case of a 65-year-old man with a history of coronary artery disease (CAD) status post-myocardial infarction, who underwent coronary bypass graft surgery, ischemic cardiomyopathy, chronic heart failure with reduced ejection fraction (HFrEF) with left ventricular ejection fraction of 30%-35% diagnosed in 2022, atrial flutter status post-ablation, and chronic kidney disease stage II who was found to have LV apical aneurysm with a newly developed left ventricular apical thrombus on transthoracic echocardiogram (TTE). The patient had been prescribed apixaban for stroke prevention; however, he reported inconsistent medication adherence. A repeat TTE a few months later revealed the apical thrombus again despite prescribed anticoagulation. The patient remained asymptomatic. Cardiac magnetic resonance imaging (CMR) was planned for further thrombus characterization and risk assessment. This case highlights the occurrence of LVT in chronic HFrEF outside the traditional post-myocardial infarction setting and emphasizes the importance of medication adherence in preventing thrombus formation. We review current evidence regarding LVT management, emerging data supporting direct oral anticoagulants (DOACs), and factors associated with thrombus persistence and recurrence. Additionally, we discuss evolving approaches to risk stratification incorporating thrombus morphology, ventricular remodeling, artificial intelligence (AI)-assisted imaging, and genomic risk assessment. This case underscores the limitations of generalized treatment recommendations and highlights the need for individualized, risk-adapted management strategies to optimize anticoagulation duration and reduce thromboembolic complications in patients with LVT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.